A prospective observational cohort study fo deferential ejection and reverse remodeling effect after SAVR and TAVI

A prospective observational cohort study fo deferential ejection and reverse remodeling effect after SAVR and TAVI - DEAREST2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038856

Enrollment

150

Registered

2020-01-01

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Aortic valve stenosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe aortic stenosis with pressure range over 40mmHg

Exclusion criteria

Exclusion criteria: 1) Patients with contraindications for transesophageal echocardiography (TEE) insertion 2) Other patients who are deemed inappropriate by the principal investigator

Design outcomes

Primary

Measure	Time frame
Maximum displacement distance and time of tricuspid and mitral annulus in speckle tracking method	—

Secondary

Measure	Time frame
1) Cardiac ultrasonography findings LAD, LVDd, LVDs, IVSth, EF, FS, LVmass, LVMI, RWT, PW: E, PW: A, E / A, DT, e ', s' E / e' LV tei index, RWMA, valvular disease, aortic valve pressure difference, SV, CO, Zva, GLS, TAPSE, MAPSE, TASV, MASV 2) cardiac output Echocardiographic findings and cardiac output measurement data by Flo-trac and PAC 3) Patient outcome, preoperative examination data 28-day outcome (mortality, occurrence of heart failure symptoms, occurrence of heart-related events) 1-year outcome (mortality, occurrence of heart failure symptoms, occurrence of heart-related events) Preoperative examination data (Hb, Plt, Alb, Cre, (GFR, BNP)	—

Measure

Time frame

1) Cardiac ultrasonography findings LAD, LVDd, LVDs, IVSth, EF, FS, LVmass, LVMI, RWT, PW: E, PW: A, E / A, DT, e ', s' E / e' LV tei index, RWMA, valvular disease, aortic valve pressure difference, SV, CO, Zva, GLS, TAPSE, MAPSE, TASV, MASV 2) cardiac output Echocardiographic findings and cardiac output measurement data by Flo-trac and PAC 3) Patient outcome, preoperative examination data 28-day outcome (mortality, occurrence of heart failure symptoms, occurrence of heart-related events) 1-year outcome (mortality, occurrence of heart failure symptoms, occurrence of heart-related events) Preoperative examination data (Hb, Plt, Alb, Cre, (GFR, BNP)

—

Countries

Japan

Contacts

Public ContactTakashi Ota

Shonan Kamakura General Hospital Anesthesiology

otacchi@gmail.com0467461717

Outcome results